B-type natriuretic peptide proteolytic assay for cardiovascular disease risk assessment
Described herein are methods for assessing the risk of cardiovascular disease in a subject in need thereof by detecting the presence of one or more cleavage products of the one or more natriuretic peptides over a period of time, wherein the presence of one or more cleavage products is indicative of an increased risk of the subject developing cardiovascular disease. Provided herein are compositions and kits comprising a non-natural natriuretic peptide comprising one or more D-amino acids. Also provided herein are methods of diagnosing a subject for a disease and treating the subject for the disease, wherein the method comprises the use of a non-natural natriuretic peptide comprising one or more D-amino acids.
1. A method of detecting two or more cleavage products of one or more natriuretic peptides in a biological sample, comprising:
obtaining a biological sample from a subject, wherein the biological sample comprises one or more proteases, wherein the biological sample is plasma, blood, or serum, and wherein the subject is at risk of developing cardiovascular disease;
adding a quantity of one or more natriuretic peptides to the biological sample, wherein the natriuretic peptides are selected from the group consisting of brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP);
incubating the biological sample to form an incubated sample;
injecting the incubated sample into a separation capillary of a capillary electrophoresis/electrospray ionization mass spectrometer;
operating the capillary electrophoresis/electrospray ionization mass spectrometer to detect two or more cleavage products of the one or more natriuretic peptides over a period of time; and
detecting the two or more cleavage products of the one or more natriuretic peptides, wherein the cleavage products are selected from the group consisting of BNP 3-30, BNP 3-29, BNP 3-32, BNP 1-30, BNP 1-29, BNP 1-28, BNP 2-31, BNP 4-30, BNP 4-29, BNP 4-27, BNP 5-32, BNP 5-31, BNP 5-29, BNP 4-32, BNP 4-31, ANP 4-28, ANP 4-25, ANP 1-25, ANP 1-8, and ANP 9-28.
2. The method of claim 1 , further comprising selecting a treatments for cardiovascular disease for the subject, wherein the treatment is selected from the group consisting of pharmacological therapy, surgery, and combinations thereof.
3. The method of claim 1 , wherein the proteases are selected from the group consisting of neutral endopeptidase, dipeptidylpeptidase IV, and insulin degrading enzyme.
4. The method of claim 1 , wherein the period of time is up to 1 hour.
5. The method of claim 1 , wherein the period of time is up to 14 hours.
6. The method of claim 1 , wherein the cleavage products are selected from the group consisting of BNP 3-30, BNP 3-29, BNP 3-32, and BNP 1-30.
7. The method of claim 1 , wherein the cleavage products are selected from the group consisting of BNP 3-30, BNP 3-29, BNP 3-32, BNP 1-30, BNP 5-29, BNP 4-29, BNP 1-28, BNP 1-29, BNP 4-31, and BNP 4-32.
8. The method of claim 6 , wherein the cleavage products are not modified.
9. The method of claim 6 , wherein the cleavage products are modified.
10. The method of claim 9 , wherein the modification is oxidation at the methionine residue.
11. The method of claim 1 , wherein the quantity of one or more natriuretic peptides added to the sample is about any one or more of 10 ng/μL, 50 ng/μL, 75 ng/μL, 100 ng/μL, 125 ng/μL, 150 ng/μL, 175 ng/μL, 200 ng/μL, 225 ng/μL, 250 ng/μL, 275 ng/μL, 300 ng/μL, 350 ng/μL, 375 ng/μL, 400 ng/μL, 450 ng/μL, 475 ng/μL, or 500 ng/μL.
12. The method of claim 1 , wherein the cardiovascular disease is heart failure, arterial fibrillation or combination thereof.
13. The method of claim 1 , further comprising: comparing the two or more cleavage products of the one or more natriuretic peptides from the subject to two or more cleavage products of one or more natriuretic peptides from a reference sample.
14. The method of claim 13 , further comprising: making an assessment of the subject based on the comparison, wherein the assessment is a determination of the risk of developing cardiovascular disease.
15. The method of claim 13 , wherein the reference sample is obtained from a healthy subject.
16. The method of claim 13 , wherein the reference sample is obtained from a subject that has been treated for cardiovascular disease.
17. The method of claim 13 , wherein the reference sample is obtained from the subject at an earlier point in time.
18. The method of claim 13 , wherein the reference sample is obtained from the subject before the subject is treated for cardiovascular disease.
19. The method of claim 1 , further comprising detecting the one or more natriuretic peptides over a period of time.
20. A method of obtaining a proteolytic profile of two or more cleavage products of one or more L-natriuretic peptides, in a biological sample, the method comprising:
obtaining a biological sample from a subject, wherein the biological sample comprises one or more proteases, and wherein the biological sample is plasma, blood, or serum;
adding an amount of one or more L-natriuretic peptides to the biological sample, wherein the L-natriuretic peptides are selected from the group consisting of natural brain natriuretic peptide (natural BNP), natural atrial natriuretic peptide (natural ANP), cleavable synthetic brain natriuretic peptide (cleavable synthetic BNP), and cleavable synthetic atrial natriuretic peptide (cleavable synthetic ANP);
adding an amount of an internal standard to the biological sample, wherein the internal standard comprises one or more non-natural natriuretic peptides, one or more non-natural cleavage peptidoforms, or a combination thereof;
incubating the biological sample to form an incubated sample;
injecting the incubated sample into a separation capillary of a capillary electrophoresis/electrospray ionization mass spectrometer;
operating the capillary electrophoresis/electrospray ionization mass spectrometer to detect an amount of two or more cleavage products of the one or more L-natriuretic peptides and an amount of the internal standard over a period of time; and
detecting the amount of the two or more cleavage products of the one or more L-natriuretic peptides and the amount of the internal standard, wherein the cleavage products are selected from the group consisting of BNP 3-30, BNP 3-29, BNP 3-32, BNP 1-30, BNP 1-29, BNP 1-28, BNP 2-31, BNP 4-30, BNP 4-29, BNP 4-27, BNP 5-32, BNP 5-31, BNP 5-29, BNP 4-32, BNP 4-31, ANP 4-28, ANP 4-25, ANP 1-25, ANP 1-8, and ANP 9-28.
21. The method of claim 1 , further comprising administering a treatment for cardiovascular disease to the subject, wherein the treatment is selected from the group consisting of pharmacological therapy, surgery, and combinations thereof.
22. The method of claim 20 , further comprising quantifying the amount of the two or more L-natriuretic peptide cleavage products by comparing the amount of two or more L-natriuretic peptide cleavage products with the amount of the internal standard to obtain a proteolytic profile of the subject.
23. The method of claim 22 , further comprising comparing the proteolytic profile from the subject to a proteolytic profile from a reference sample, and making an assessment of the subject based on the comparison, wherein the assessment is a diagnosis of cardiovascular disease.
24. The method of claim 23 , further comprising administering a treatment for cardiovascular disease to the subject, selecting a treatment for cardiovascular disease for the subject, or providing a treatment for cardiovascular disease for the subject based on the assessment, wherein the treatment is selected from the group consisting of pharmacological therapy, surgery, and combinations thereof.